Aurinia Pharmaceuticals: Strong Buy Rating Backed by Robust Financials and Promising Pipeline

Aurinia Pharmaceuticals (AUPH – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst David Martin PhD from Bloom Burton maintained a Buy rating on the stock and has a $10.00 price target.

David Martin PhD has given his Buy rating due to a combination of factors including Aurinia Pharmaceuticals’ strong financial performance and promising product pipeline. The company has reported first-quarter results for 2025 that exceeded expectations, particularly with the sales of their product Lupkynis, which showed significant year-over-year growth.
Furthermore, despite the competitive pressures from generic alternatives, Aurinia has maintained its revenue guidance, indicating confidence in its market position. Additionally, the anticipation of upcoming results from their AUR200 Phase 1 trials suggests potential future growth opportunities, reinforcing the positive outlook on the stock.

In another report released on May 12, TD Cowen also maintained a Buy rating on the stock with a $11.00 price target.

Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AUPH in relation to earlier this year.